James Riley

Professor

University of Pennsylvania

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

James Riley is a Professor at the University of Pennsylvania, located in the United States. His research focuses on cell therapies, particularly in the context of viral diseases such as HIV, and examines gene-modified T cell therapies. He has published extensively on topics including the enhancement of T cell functionality and the mechanisms of immune response in cancer and viral infections.

Articles (13)

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (5)

Elizabeth Hexner

UNITED STATES

View details

Neil C. Sheppard

University of Pennsylvania

UNITED STATES

View details

Su Kyung Kim

Assistant Professor

Thomas Jefferson University

UNITED STATES

View details

Stephan Grupp

Section Chief, Cellular Therapy and Transplant

Children's Hospital of Philadelphia

UNITED STATES

View details

Adam Cohen

Associate Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

James Riley

Research Interests

Explore related searches

Contact this professor

About

Articles (13)

Cell therapies for viral diseases: a new frontier

Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies

Augmenting TCR signal strength and ICOS costimulation results in metabolically fit and therapeutically potent human CAR Th17 cells.

Aberrant expression of GOLM1 protects ALK+ anaplastic large cell lymphoma from apoptosis by enhancing BCL-XL stability.

Chimeric antigen receptors enable superior control of HIV replication by rapidly killing infected cells

Generation of non-human primate CAR Tregs using artificial antigen-presenting cells, simian tropic lentiviral vectors, and antigen-specific restimulation

HIV-1–Infected CD4+ T Cells Present MHC Class II–Restricted Epitope via Endogenous Processing

CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication

Ultrasensitive antigen density discrimination by synNotch

Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation

Genetic engineering of T cells for immunotherapy.

Challenges and Opportunities of Using Adoptive T-Cell Therapy as Part of an HIV Cure Strategy

How to kill Treg cells for immunotherapy

Collaborators (5)

Elizabeth Hexner

Neil C. Sheppard

Su Kyung Kim

Stephan Grupp

Adam Cohen

Make your next move.